Skip to main content
. 2017 Aug 2;8(38):64191–64202. doi: 10.18632/oncotarget.19828

Figure 5. Predictive and prognostic value of each individual lncRNA as well as the combined seven-lncRNA signature.

Figure 5

(A) Risk scores of the combined seven-lncRNA signature between IR and CR EOC patient groups. (B) Sensitivity analysis of the combined seven-lncRNA signature between IR and CR EOC patient groups. (C) Correlation between risk scores and progression-free survival, as well as overall survival. (D) The Kaplan-Meier plotter analysis of overall survival between low risk and high risk EOC patient groups on the basis of the combined seven-lncRNA signature. (E) The Kaplan-Meier plotter analysis of progression-free survival between low risk and high risk EOC patient groups on the basis of the combined seven-lncRNA signature. IR: incomplete response; CR: complete response; OS: overall survival; OV: ovarian cancer; PFS: progression-free survival; MST: mean survival time.